In Vitro Diagnostics – IVD News
Curetis Validation of Blood Culture Cartridge
Curetis Starts Final Validation Study for New Unyvero Blood Culture Application Cartridge – Data and CE-IVD launch expected in Q2, 2016 – Company also prepares launch of 2nd generation ITI Application Cartridge and novel product for intra-abdominal infections Amsterdam, the Netherlands and Holzgerlingen, Germany, February 23, 2016 — Curetis N.V. (the “Company” and, together with…
Read MoreCuretis Expands Commercial Team
Curetis Expands Commercial Team – Company hires Willem Haagmans as Head of Sales EMEA – Amsterdam, the Netherlands and Holzgerlingen, Germany, February 3, 2016 — Curetis N.V. (the “Company” and, together with Curetis AG, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced the expansion of its commercial and general administrative team. As of…
Read MoreCuretis Medical Advisory Board
Curetis Establishes Medical Advisory Board with Internationally Renowned Experts Curetis AG, 11 Jan 16, Amsterdam, The Netherlands, and Holzgerlingen, Germany, January 11, 2016 – Curetis N.V., a developer of next-level molecular diagnostic solutions for syndromic infectious disease testing, today announced the establishment of its Medical Advisory Board (MAB). Initially, it will consist of four leading experts…
Read MoreEpigenomics Receives Notice of FDA Pending Approval
Epigenomics Receives FDA Notification About Status of Pending Approval Decision for Epi proColon® Berlin, Germany, January 8, 2016 – Epigenomics AG, Berlin, Germany, (Frankfurt Prime Standard: ECX; ISIN: DE000A11QW50) the German-American cancer molecular diagnostics company, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that the already submitted and available…
Read MoreCuretis IPO
Curetis AG / Curetis IPO priced at EUR 10.00 per Share; raises EUR 40 million . Holzgerlingen, Germany, November 10, 2015 — Curetis N.V.[1] (the “Company” and, together with Curetis AG, “Curetis“), a developer of next-level molecular diagnostic solutions, today announces the completion of its initial public offering, which was launched on October 28, 2015…
Read MoreEpigenomics Update at AMP 2015 Annual Meeting
http://www.epigenomics.com/en/news-investors/news-media/press-releases/latest-news/article/epigenomics-ag-gibt-ein-update-ueber-bluttests-zur-krebsfrueherkennung-auf-der-jahrestagung-2015-der.html
Read MoreGBC Attends 2014 ASM Conference
Global BioClinical (GBC) attended the 2014 American Society for Microbiology (ASM) meeting in Boston. MAhttp://gm.asm.org/
Read More2013 ICAAC Poster
GBC Attended the 2013 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, Colorado September 9 – 13, 2013 Click here for Poster PDF: [wpdm_file id=8] Poster Title: Evaluation of a Molecular Multiplex Test For Detection of Respiratory Microorganism and Antibiotic Resistance Genes in Clinical Specimens Authors: M. Malczynski1, M. Klein2, N. Mucci3, K. Schwarzer2, A.…
Read MoreBiopreservation and Biobanking Publication
Neil R. Mucci of GBC Leads caHUB Committee in Developing, Summarizing and Publishing Recommendations that Promote Availability of Biospecimens for Research SEATTLE, April 25, 2013 Global BioClinical (GBC) is pleased to announce the publication of an article in the April 2013 issue of Biopreservation and Biobanking titled: Meeting Research Needs with Postmortem Biospecimen Donation: Summary of Recommendations for…
Read MoreGBC Supports Curetis AG Trial in U.S.
Curetis AG Initiates Clinical Trial in the U.S. Towards FDA Clearance December 6, 2012 – 10:44:28 – Prospective Multi-Center Trial to Enroll Over 2,000 Clinical Samples (live-PR.com) – Holzgerlingen, Germany, December 6, 2012 — Curetis AG today announced the start of a clinical trial of its Unyvero™ System and the corresponding LRT (lower respiratory tract)…
Read More